| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 29, 2024 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Timothy Lorber, CPA, as the Company Chief Financial Officer. The Company's current Chief Financial Officer, Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and will assume the Vice President, Regulatory position on a full-time basis. Mr. Lorber is a CPA with more than 40 years of profession
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2024. Shuttle Pharma's recent highlights include the following: Successfully dosed first three patients in the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with brain tumors (glioblastoma). Ropidoxuridine is Shuttle Pharma's lead
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the pricing of its "reasonable best efforts" public offering with a health-care focused institutional investor for the purchase and sale of up to 2,950,820 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,950,820 shares of common stock at a combined offering price of $1.525 per share and accompanying warrant, priced at-the-market under
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that, during the third quarter of this year, it paid off the entirety of the outstanding balance due under its Senior Secured Convertible Note ("Note") issued on January 11, 2023. The initial balance of the Note was $4.3 million and was originally repayable over a 26-month period ending March 11, 2025. During the term of the note, Shuttle Pharma made periodic cash payments totaling $1.3 million
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)
SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC). The published manuscript, titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, prefere
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDAQ:DRMA) stock rose 12.8% to $3.7. The company's market cap stands at $1.6 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock moved upwards by 7.88% to $0.47. The company's market cap stands at $7.8 million. Ocular Therapeutix (NASDAQ:OCUL) shares rose 7.25% to $6.36. The market value of their outstanding shares is at $985.0 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 6.02% to $0.89. The company's market cap stands at $33.4 million. Virios Therapeutics (NASDAQ:VIRI) shares
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)